Hospital Clínico Universitario de Santiago - CHUS
Hospital Clínico Universitario de Santiago - CHUS
Rúa da Choupana, s/n, 15706 Santiago de Compostela, A Coruña
Select an option
I am a doctor
I am a sponsor
Open studies
Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy - Astefania - Hoffmann-La RocheSee more
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) - heredERA - Hoffmann-La RocheSee more
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Cervical cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Diffuse sclerosis
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms - VITALISScE™ - Boehringer IngelheimSee more
Head and neck cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Lung cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Ovarian cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Solid tumors
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
